Summary of Study ST001215

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000811. The data can be accessed directly via it's Project DOI: 10.21228/M8VD62 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001215
Study TitleEffect of Mirabegron Treatment on serum lipidome
Study SummaryDetermine the lipidome changes in the serum of human subjects treated with a single dosage (200mg) of the beta-3 adrenoceptor agonist Mirabegron.
Institute
Joslin Diabetes Center
Last NameLeiria
First NameLuiz
AddressOne Joslin Place, 02215, Boston, MA-USA
Emailluiz.leiria@joslin.harvard.edu
Phone617-309-1967
Submit Date2016-10-23
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2019-09-23
Release Version1
Luiz Leiria Luiz Leiria
https://dx.doi.org/10.21228/M8VD62
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000811
Project DOI:doi: 10.21228/M8VD62
Project Title:12-LOX metabolites in cold adaptation
Project Summary:The goal of this project is to understand the role of the enzyme 12-lipoxygenase in the adaptive thermogenesis. We found this enzyme is activated by cold stimulation, then producing lipid metabolites in adipose tissue and releasing them into the circulation to regulate fuel utilisation and thermogenic pathways required for the cold adaptation.
Institute:Joslin Diabetes Center
Department:Integrative Physiology and Metabolism
Laboratory:Yu-Hua Tseng lab
Last Name:Leiria
First Name:Luiz
Address:One Joslin Place, Boston, MA-USA, 02215
Email:luiz.leiri@joslin.harvard.edu
Phone:1 6173091967

Subject:

Subject ID:SU001282
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA085891309-14 MMirabegron
SA085892309-17 MMirabegron
SA085893309-18 MMirabegron
SA085894309-13 MMirabegron
SA085895309-15 MMirabegron
SA085896309-05 MMirabegron
SA085897309-12 MMirabegron
SA085898309-06 MMirabegron
SA085899309-02 MMirabegron
SA085900309-04 MMirabegron
SA085901309-03 MMirabegron
SA085902309-13 PPlacebo
SA085903309-12 PPlacebo
SA085904309-02 PPlacebo
SA085905309-18 PPlacebo
SA085906309-15 PPlacebo
SA085907309-04 PPlacebo
SA085908309-17 PPlacebo
SA085909309-03 PPlacebo
SA085910309-14 PPlacebo
SA085911309-05 PPlacebo
SA085912309-06 PPlacebo
Showing results 1 to 22 of 22

Collection:

Collection ID:CO001276
Collection Summary:Human plasma was acquired from a previously performed clinical trial (Cypess et al., 2015) registered with ClinicalTrials.gov (NCT01783470) and had the FDA Investigational New Drug (IND) registration number 116246. It was approved by the Human Studies Institutional Review Boards of Beth Israel Deaconess Medical Center (BIDMC) and Joslin Diabetes Center (JDC). Blood samples were collected 180 minutes after oral dosing. 180 minutes is the corresponding T max (time after administration of a drug when the maximum plasma concentration is reached) found for mirabegron in men (Baskin et al., Diabetes 2018).
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR001297
Treatment Summary:Healthy volunteers were recruited through electronic advertisements and provided written informed consent. The subjects were given a single oral dose of mirabegron, 200 mg.

Sample Preparation:

Sampleprep ID:SP001290
Sampleprep Summary:Aliquots of 100 µL plasma were taken, depending on the experiment. A mixture of deuterium-labeled internal standards was added to each aliquot, followed by 3x volume of sample of cold methanol (MeOH). Samples were vortexed for 5 minutes and stored at 31 −20 °C overnight. Cold samples were centrifuged at 14,000g for 10 minutes, and the supernatant was then transferred to a new tube and 3 mL of acidified H 2 O (pH 3.5) was added to each sample prior to C18 SPE. The methyl formate fractions were collected, dried under nitrogen, and reconstituted in 50 µL MeOH:H 2 O (1:1, by vol). Samples were transferred to 0.5 mL tubes and centrifuged at 20,000g at 4 °C for 10 minutes. (35ul) of supernatant was transferred to LC–MS/MS vials for analysis using the BERG LCMS/MS mediator lipidomics platform.

Combined analysis:

Analysis ID AN002026
Analysis type MS
Chromatography type Reversed phase
Chromatography system Ekspert MicroLC 200 system
Column Phenomenex Synergi Fusion-RP capillary C18 (150 × 0.5 mm,4um)
MS Type ESI
MS instrument type QTOF
MS instrument name ABI Sciex 5600+ TripleTOF
Ion Mode NEGATIVE
Units Peak Area

Chromatography:

Chromatography ID:CH001467
Instrument Name:Ekspert MicroLC 200 system
Column Name:Phenomenex Synergi Fusion-RP capillary C18 (150 × 0.5 mm,4um)
Chromatography Type:Reversed phase

MS:

MS ID:MS001879
Analysis ID:AN002026
Instrument Name:ABI Sciex 5600+ TripleTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:MS analysis was performed on a SCIEX TripleTOF® 5600+ system using the HR-MRM strategy consisting of a TOF MS experiment looped with multiple MS/MS experiments. MS spectra were acquired in high-resolution mode (>30,000) using a 100-ms accumulation time per spectrum. Fullscan MS/MS was acquired in high sensitivity mode, with an accumulation time optimized per cycle. Collision energy was set using rolling collision energy with a spread of 15V. The identity of a component was confirmed using PeakView® software (SCIEX), and quantification was performed using MultiQuant™ software (SCIEX).
Ion Mode:NEGATIVE
  logo